Clinical outcomes of gastrointestinal stromal tumor in southern Thailand
| Autor: | Walawee Chaiyapan, Kittima Pornsuksiri, Wanwisa Maneechay, Siripong Chewatanakornkul, Samornmas Kanngurn, Surasak Sangkhathat |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
GiST business.industry medicine.medical_treatment Gastroenterology Imatinib medicine.disease Primary tumor digestive system diseases Metastasis Targeted therapy Surgery Oncology Medicine Original Article Stromal tumor business neoplasms Progressive disease Survival analysis medicine.drug |
| Zdroj: | World Journal of Gastrointestinal Oncology. 4:216 |
| ISSN: | 1948-5204 |
| Popis: | AIM: To review a single institutional experience in clinical management of gastrointestinal stromal tumors (GIST) and analyze for factors determining treatment outcome. METHODS: Clinicopathological data of patients with a diagnosis of GIST who were treated at our institute during November 2004 to September 2009 were retrospectively reviewed. RESULTS: Ninety-nine cases were included in the analysis. Primary tumor sites were at the stomach in and small bowel in 44% and 33%, respectively. Thirty-one cases already had metastasis at presentation and the most common metastatic site was the liver. Sixty-four cases (65%) were in the high-risk category. Surgical treatment was performed in 77 cases (78%), 3 of whom received upfront targeted therapy. Complete resection was achieved in 56 cases (73% of operative cases) and of whom 27 developed local recurrence or distant metastasis at a median duration of 2 years. Imatinib was given as a primary therapy in unresectable cases (25 cases) and as an adjuvant in cases with residual tumor (21 cases). Targeted therapy gave partial response in 7 cases (15%), stable disease in 27 cases (57%) and progressive disease in 13 cases (28%). Four-year overall survival was 74% (95% CI: 61%-83%). Univariate survival analysis found that low-risk tumor, gastric site, complete resection and response to imatinib were associated with better survival. CONCLUSION: The overall outcomes of GIST can be predicted by risk-categorization. Surgery alone may not be a curative treatment for GIST. Response to targeted therapy is a crucial survival determinant in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|